10 GLP-1 Contraindications Every Perimenopausal Woman Should Know

Introduction

Understanding the implications of GLP-1 therapy is crucial for perimenopausal women as they navigate their health options. These medications are becoming increasingly popular for weight management, making it essential to recognize their contraindications. Such contraindications can significantly impact treatment outcomes. Women with specific health histories may face unique challenges when considering these therapies. By being aware of these contraindications, women can make informed decisions about their health and treatment options.

Severe Gastrointestinal Conditions: A Key Contraindication for GLP-1 Therapy

Women with severe gastrointestinal conditions, such as gastroparesis or inflammatory bowel disease, should avoid due to the GLP-1 contraindications associated with potential worsened side effects. These conditions can exacerbate the gastrointestinal issues commonly associated with GLP-1 treatments, which is why it is important to be aware of GLP-1 contraindications, including:

• Nausea
• Vomiting
• Bloating
• Stomach discomfort
• Constipation

The mechanism of GLP-1s, which delays gastric emptying, can intensify these symptoms and highlight the importance of considering GLP-1 contraindications, leading to significant discomfort and potential complications. Therefore, a comprehensive medical history is crucial to identify any such conditions before starting therapy. Healthcare professionals emphasize the importance of careful monitoring and consideration of individual factors in these cases.

This caution is particularly relevant, as gastrointestinal side effects are among the most frequently reported issues. Many patients experience adverse reactions that could hinder their treatment success. Understanding these risks can help in making informed decisions about therapy options.

Thyroid Cancer History: Important Consideration for GLP-1 Candidates

Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should consider the when avoiding certain medications. Research indicates a potential link between glucagon-like peptide-1 treatment and thyroid tumors in animal models. This finding underscores the need for caution regarding [GLP-1 contraindications](https://tydewellness.com/learn/10-alternatives-to-wegovy-for-sustainable-weight-loss) when prescribing these medications to at-risk groups.

Furthermore, a thorough evaluation of thyroid health is essential before initiating treatment. Ensuring that patients are well-informed about the risks can help in making safer healthcare decisions.

History of Pancreatitis: A Significant Risk Factor for GLP-1 Use

Women with a history of pancreatitis should approach this type of therapy cautiously because of the . Recent studies suggest that while certain therapies may not significantly increase the risk of pancreatitis, the [[GLP-1 contraindications](https://www.tydewellness.com/learn/how-long-has-semaglutide-been-studied-for-womens-health/)](https://tydewellness.com/learn/how-much-does-tirzepatide-cost-key-factors-and-savings-strategies) regarding the potential for recurrence remain a concern. At Tyde Wellness, clinicians conduct thorough evaluations of each patient’s history. This ensures that those at significant risk receive tailored alternatives that prioritize their safety.

Our customized peptide therapy programs feature full-strength medications for glucose-dependent insulinotropic polypeptide. These programs come with dedicated support from expert physicians and health coaches. The advantage of this comprehensive approach is that it enables a thorough strategy for weight reduction and health enhancement. By focusing on individual needs, we aim to provide effective solutions that promote overall well-being.

Allergic Reactions: A Critical Contraindication for GLP-1 Medications

Individuals with a known hypersensitivity to receptor agonists should consider the [GLP-1 contraindications](https://bmj.com/content/388/bmj.r390) and avoid these medications. Allergic reactions can vary significantly in severity, from mild skin irritations to life-threatening anaphylaxis. Recent data shows that [hypersensitivity reactions occur in about 2 to 4 percent of users](https://pmc.ncbi.nlm.nih.gov/articles/PMC9989345) during large clinical trials. Specifically, the incidence rate of anaphylaxis is reported at 3.6 per 10,000 person-years for semaglutide and 6.0 per 10,000 person-years for exenatide. This highlights the importance of vigilance in prescribing these therapies.

Healthcare providers must conduct a thorough allergy history before prescribing receptor agonists, keeping in mind the GLP-1 contraindications to safeguard patient health. For instance, a study involving 696,089 new users of these medications identified 188 cases of anaphylaxis, underscoring the real-world implications of such reactions. Furthermore, recent data from the UK indicates that there have been 82 deaths linked to adverse reactions related to agonists, emphasizing the seriousness of hypersensitivity.

Experts stress that understanding GLP-1 contraindications related to hypersensitivity is crucial for effectively managing treatment plans. This ensures that patients receive , ultimately enhancing their overall health outcomes.

Pregnancy and Nursing: Contraindications for GLP-1 Therapy

Certain medications are not recommended during pregnancy and nursing due to insufficient safety information regarding their effects on fetal growth and infant health. Research shows that exposure to receptor agonists in the first trimester may pose risks, including fetal growth restriction and structural abnormalities. For instance, studies indicate that the rate of significant birth defects in the group taking the medication was 2.6%, compared to 2.3% in women with diabetes and 3.9% in those who are overweight or obese. Additionally, the cumulative incidence of pregnancy losses in the treatment group was 23%, underscoring the need for caution.

Experts emphasize the importance of effective contraception for women on these treatments, as gastrointestinal side effects can impair the absorption of oral contraceptives, increasing the risk of unintended pregnancies. Non-oral contraceptives, such as IUDs, implants, patches, or condoms, appear unaffected by certain diabetes medications. Healthcare providers should prioritize discussions about safe weight management strategies during pregnancy, such as structured behavioral counseling and nutrition counseling, which can help reduce excessive gestational weight gain and lower the risk of complications like gestational diabetes.

Tyde Wellness offers that focus on hormone balance and nutrition. These programs include ‘Easy Nutrition’ meal plans and ‘Expert Support‘ coaching, empowering women to reclaim their health during this critical time. The latest guidelines recommend that women discontinue specific treatments at least two months before attempting to conceive to ensure optimal health outcomes for both mother and child.

Eating Disorders: A Contraindication for GLP-1 Treatment

Women with a history of eating disorders, such as anorexia or bulimia, should avoid GLP-1 therapy due to the associated with its potential effects on appetite and satiety signals. These medications can trigger or worsen disordered eating behaviors, which underscores the importance of understanding [[GLP-1 contraindications](https://www.tydewellness.com/learn/10-benefits-of-a-semaglutide-subscription-for-weight-loss-success/)](https://tydewellness.com/drkellykassick) that pose significant risks for this population.

Furthermore, a thorough psychological assessment is essential to ensure that patients are stable and prepared for weight management interventions. This evaluation helps to identify any underlying issues that may complicate treatment and supports a safer approach to weight loss.

Psychological Distress: A Consideration Before Starting GLP-1 Therapy

Before starting glucagon-like peptide-1 therapy, women experiencing significant psychological distress, such as anxiety or depression, should undergo a thorough assessment to check for GLP-1 contraindications. Mental health plays a crucial role in treatment adherence and outcomes, making it essential to address these concerns for effective weight management.

At Tyde Wellness, we prioritize a personalized approach. Our initial consultation evaluates your health, goals, and mental well-being, including your eligibility for our weight loss program. Collaborating with mental health professionals can enhance your journey, and as a Tyde Circle member, you’ll connect with a supportive community that empowers women through shared experiences and encouragement.

This holistic support is vital for achieving and overall wellness. By addressing both physical and mental health, we aim to create a comprehensive strategy that fosters long-term success.

Medication Interactions: Risks Associated with GLP-1 Use

These treatments can interact with various substances, leading to GLP-1 contraindications that may diminish their effectiveness or heighten the risk of adverse effects. For instance, using them alongside insulin or other diabetes medications raises the risk of hypoglycemia, highlighting the importance of understanding GLP-1 contraindications, as this can lead to serious health complications. A notable case involved a patient who faced significant lamotrigine toxicity after starting a glucagon-like peptide-1 receptor agonist, which underscores the importance of being aware of GLP-1 contraindications and monitoring for drug interactions. Additionally, patients on tirzepatide have reported gastrointestinal side effects, complicating their overall treatment plans.

The simultaneous use of insulin and related treatments is quite prevalent, with over 15 million Americans relying on these medications, many of whom may also be using insulin. This combination requires due to GLP-1 contraindications to prevent potential hypoglycemic episodes. Pharmacists stress the importance of comprehensive drug reviews to identify possible interactions and adjust treatment plans as needed. They encourage individuals to engage in open discussions with their healthcare providers about all medications they are taking, including over-the-counter products and supplements, to ensure the safe and effective use of these therapies.

Moreover, research indicates that therapeutic errors, such as incorrect dosing or timing, are common with these treatments, further complicating their administration. Patients are advised to establish a system to remember their dosing schedules and to consult with pharmacists for guidance on proper administration techniques. By taking proactive steps in medication management, individuals can mitigate risks and enhance the effectiveness of their treatment.

Medical Assessment: Essential Before Initiating GLP-1 Therapy

Before initiating GLP-1 therapy, a thorough medical assessment is essential. This assessment should encompass:

• A detailed medical history
• A physical examination
• Necessary laboratory tests to evaluate kidney function, liver function, and overall health status

Identifying any GLP-1 contraindications or risk factors is crucial for ensuring safety and optimizing treatment outcomes.

Dr. Naser Gharaibeh emphasizes the importance of this evaluation, stating, “A thorough evaluation is essential to tailor the treatment plan effectively and ensure patient safety.” Additionally, studies reveal that around 30% of women beginning GLP-1 therapy may have underlying renal issues that could impact treatment efficacy. Dr. Louis Arrone notes, “When kidney function is compromised, it can significantly impact how medications are metabolized, making these evaluations critical.”

By adhering to these guidelines, healthcare providers can better customize treatment plans, ultimately enhancing the likelihood of successful weight management and improved health outcomes for patients. Furthermore, as part of the Tyde Wellness community, women are encouraged to engage with Tyde Circle members. This collaboration fosters a where insights are shared, empowering women throughout their wellness journeys.

Understanding GLP-1 Contraindications: A Summary of Key Considerations

Women considering this treatment should be aware of several critical that may impact their medical journey. These GLP-1 contraindications include:

1. Severe gastrointestinal conditions
2. A history of thyroid cancer
3. Pancreatitis
4. Allergic reactions
5. The implications of pregnancy and nursing

Furthermore, individuals with eating disorders or psychological distress should approach GLP-1 therapy with caution due to the GLP-1 contraindications, as these factors can complicate treatment outcomes.

It’s also essential to consider potential interactions with other medications. A thorough medical assessment is crucial to ensure both safety and efficacy in treatment. By understanding GLP-1 contraindications, healthcare providers can better support their patients in making informed decisions about their weight management options. This understanding ultimately leads to more successful outcomes.

Conclusion

Understanding the contraindications of GLP-1 therapy is essential for perimenopausal women considering this treatment option. Recognizing specific conditions that may complicate GLP-1 usage empowers women to make informed decisions about their health and wellness. With the right knowledge, women can navigate the complexities of weight management and overall health more effectively.

The article highlights several critical contraindications, including:

1. Severe gastrointestinal conditions
2. A history of thyroid cancer
3. Pancreatitis
4. Allergic reactions
5. Considerations surrounding pregnancy and nursing

Furthermore, it emphasizes the importance of psychological well-being and the potential for medication interactions. Each of these factors significantly influences the suitability of GLP-1 therapy for individual patients, necessitating thorough medical assessments and tailored treatment plans.

Ultimately, being proactive about understanding GLP-1 contraindications can lead to safer and more effective management of health concerns. Women are encouraged to engage in open discussions with healthcare providers, ensuring that their unique medical histories and needs are thoroughly considered. This approach not only enhances the chances of successful treatment outcomes but also fosters a supportive community where women can thrive in their health journeys.

Frequently Asked Questions

What gastrointestinal conditions should women avoid GLP-1 therapy for?

Women with severe gastrointestinal conditions such as gastroparesis or inflammatory bowel disease should avoid GLP-1 medications due to potential worsened side effects.

What are some common gastrointestinal side effects associated with GLP-1 treatments?

Common gastrointestinal side effects include nausea, vomiting, bloating, stomach discomfort, and constipation.

Why are GLP-1 medications contraindicated for those with severe gastrointestinal conditions?

GLP-1 medications delay gastric emptying, which can intensify gastrointestinal symptoms and lead to significant discomfort and potential complications.

What is the importance of a comprehensive medical history before starting GLP-1 therapy?

A comprehensive medical history is crucial to identify any severe gastrointestinal conditions that may contraindicate the use of GLP-1 therapy.

What should women with a history of medullary thyroid carcinoma consider regarding GLP-1 therapy?

Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should consider avoiding GLP-1 medications due to potential links to thyroid tumors.

What is the significance of evaluating thyroid health before starting GLP-1 treatment?

A thorough evaluation of thyroid health is essential to ensure patients are informed about the risks and can make safer healthcare decisions regarding GLP-1 therapy.

How should women with a history of pancreatitis approach GLP-1 therapy?

Women with a history of pancreatitis should approach GLP-1 therapy cautiously, as there are contraindications regarding the potential for recurrence of pancreatitis.

What alternatives are available for patients at significant risk when considering GLP-1 therapy?

Patients at significant risk may receive tailored alternatives that prioritize their safety, including customized peptide therapy programs that feature full-strength medications and dedicated support from healthcare professionals.

List of Sources

1. Severe Gastrointestinal Conditions: A Key Contraindication for GLP-1 Therapy

• Older Americans are quitting GLP-1 weight-loss drugs for 4 key reasons (https://foxnews.com/health/older-americans-quitting-glp-1-weight-loss-drugs-4-key-reasons)
• Who Shouldn’t Take GLP-1 Medications? – GoodRx (https://goodrx.com/classes/glp-1-agonists/who-should-not-take-glp-1?srsltid=AfmBOoqpcFWzwYR_mhBQfYWWp5P4qIwS6aXCS2lZ0FDjBASVZn4vJHKm)
• UBC (https://med.ubc.ca/news/weight-loss-drugs-linked-to-stomach-paralysis-other-serious-gastrointestinal-conditions)
• Are GLP-1 weight-loss drugs safe for older adults? (https://aamc.org/news/are-glp-1-weight-loss-drugs-safe-older-adults)
• GLP-1 Agonists and Gastrointestinal Adverse Events (https://jamanetwork.com/journals/jama/fullarticle/2810542)

2. Thyroid Cancer History: Important Consideration for GLP-1 Candidates

• Thyroid Cancer Diagnoses Rise in First Year of GLP-1 RA Use | HCPLive (https://hcplive.com/view/thyroid-cancer-diagnoses-rise-in-first-year-of-glp-1-ra-use)
• GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment – Oncology Nurse Advisor (https://oncologynurseadvisor.com/news/glp-1-ras-tied-to-higher-thyroid-cancer-risk-in-first-year-of-treatment)
• GLP-1 Medications Show Little Effect on Cancer, Study Shows (https://usnews.com/news/health-news/articles/2025-12-10/glp-1-medications-show-little-effect-on-cancer-study-shows)
• GLP-1RA and thyroid cancer: New study suggests detection bias, not causation – Mayo Clinic (https://mayoclinic.org/medical-professionals/endocrinology/news/glp-1ra-and-thyroid-cancer-new-study-suggests-detection-bias-not-causation/mac-20587812)
• GLP-1 RAs May Reduce Risk of Obesity-Related Cancers, but Social Media Misinformation Suggests They Increase Cancer Risk (https://ons.org/publications-research/voice/news-views/10-2025/glp-1-ras-may-reduce-risk-obesity-related-cancers)

3. History of Pancreatitis: A Significant Risk Factor for GLP-1 Use

• Intermountain Study Shows Weight Loss Drugs Don’t Increase Risk of Pancreatitis or Adverse Cardiac Events in Patients with High Triglycerides (https://news.intermountainhealth.org/intermountain-study-finds-weight-loss-drugs-dont-increase-risk-of-pancreatitis-or-adverse-cardiac-events-in-patients-with-high-triglycerides)
• GLP-1 medications for type 2 diabetes and obesity may lower risk of acute pancreatitis (https://endocrine.org/news-and-advocacy/news-room/2024/endo-2024-press-nassar)
• GLP-1 RAs Not Linked to Higher Pancreatitis or Cardiac Risk in Patients With High Triglycerides | www.PhysiciansWeekly.com (https://physiciansweekly.com/post/glp-1-receptor-agonists-not-linked-to-higher-pancreatitis-or-cardiac-risk-in-patients-with-high-triglycerides)

4. Allergic Reactions: A Critical Contraindication for GLP-1 Medications

• GLP-1 agonists: 82 deaths linked to adverse reactions, UK data show (https://bmj.com/content/388/bmj.r390)
• Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study (https://diabetesjournals.org/care/article/47/4/712/154237/Risk-of-Anaphylaxis-Among-New-Users-of-GLP-1)
• Ozempic and GLP-1 Drugs: Rare Risks of Pancreatitis, Gallbladder, Thyroid Issues, and Kidney Injury (https://everydayhealth.com/weight/ozempic-and-the-risk-of-severe-side-effects)
• Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC9989345)

5. Pregnancy and Nursing: Contraindications for GLP-1 Therapy

• How GLP-1 Drugs Can Affect Fertility and Birth Control (https://uhhospitals.org/blog/articles/2025/12/how-glp-1-drugs-can-affect-fertility-and-birth-control)
• GLP-1 Drugs and Pregnancy: Experts Discuss the Benefits and Risks (https://healthline.com/health-news/glp-1-drugs-pregnancy-benefits-risks)
• MHRA urges women taking weight-loss drugs to use effective contraception (https://pharmaceutical-journal.com/article/news/mhra-urges-women-taking-weight-loss-drugs-urged-to-use-effective-contraception)
• Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC11043712)

6. Eating Disorders: A Contraindication for GLP-1 Treatment

• #504: Adult Eating Disorders in the GLP-1 Era – The Curbsiders (https://thecurbsiders.com/curbsiders-podcast/504-adult-eating-disorders-in-the-glp-1-era)
• The Dark Side of the GLP-1 Weight Loss Drugs: Eating Disorders – TimmermanReport.com (https://timmermanreport.com/2025/11/the-dark-side-of-the-glp-1-weight-loss-drugs-eating-disorders)
• Doctors call for cigarette-style warning label on GLP-1 drugs like Ozempic due to this ‘very dangerous’ risk (https://nypost.com/2025/12/12/health/docs-call-for-glp-1-warning-label-due-to-very-dangerous-risk)
• Doctors worried about prescribing GLP-1s to certain patients (https://uc.edu/news/articles/2025/11/doctors-worried-about-prescribing-glp-1s-to-certain-patients.html)

7. Psychological Distress: A Consideration Before Starting GLP-1 Therapy

• GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours (https://tga.gov.au/news/safety-updates/glp-1-ras-warnings-aligned-over-potential-risk-suicidal-thoughts-or-behaviours)
• Doctors call for cigarette-style warning label on GLP-1 drugs like Ozempic due to this ‘very dangerous’ risk (https://nypost.com/2025/12/12/health/docs-call-for-glp-1-warning-label-due-to-very-dangerous-risk)
• The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy – Scientific Reports (https://nature.com/articles/s41598-024-75965-2)
• GLP-1s may improve some mental health outcomes in addition to lowering body weight (https://healio.com/news/endocrinology/20250515/glp1s-may-improve-some-mental-health-outcomes-in-addition-to-lowering-body-weight)

8. Medication Interactions: Risks Associated with GLP-1 Use

• Serious side-effects for popular weight loss drugs raising concerns (https://wjla.com/news/spotlight-on-america/serious-side-effects-for-popular-weight-loss-drugs-raising-concerns-risk-benefits-health-obesity-glp1-zepbound-wegovy-mounjaro-semiglutide-medication)
• Multidisciplinary panel highlights considerations for GLP-1 agonist use in OSA – CHEST Physician (https://chestphysician.org/annual-meeting/news/multidisciplinary-panel-highlights-considerations-for-glp-1-agonist-use-in-osa)
• lamotrigine toxicity associated with glp-1 agonist initiation: a case series (https://aesnet.org/abstractslisting/lamotrigine-toxicity-associated-with-glp-1-agonist-initiation-a-case-series)
• Overdose risks increase as demand for injectable weight-loss drugs on the rise, research finds (https://uab.edu/news/research-innovation/increase-in-overdoses-of-popular-injectable-weight-loss-medications-according-to-uab-led-study)

9. Medical Assessment: Essential Before Initiating GLP-1 Therapy

• World Health Organization (WHO) officially issues guidelines on the use of GLP-1 medications for the treatment of obesity in adults (https://valleyhealth.com/trending/world-health-organization-who-officially-issues-guidelines-use-glp-1-medications-treatment)
• World Health Organization issues first-ever guidelines for use of GLP-1 weight loss medications (https://goodmorningamerica.com/wellness/story/world-health-organization-issues-guidelines-glp-1-weight-127982111)
• WHO issues global guideline on the use of GLP-1 medicines in treating obesity (https://who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity)
• WHO Publishes GLP-1 Guidelines for Obesity Treatment | AJMC (https://ajmc.com/view/who-publishes-glp-1-guidelines-for-obesity-treatment)
• FDA approves Novo Nordisk’s Wegovy® pill, the first and only oral GLP-1 for weight loss in adults (https://prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html)

10. Understanding GLP-1 Contraindications: A Summary of Key Considerations

• Who Shouldn’t Take GLP-1 Medications? – GoodRx (https://goodrx.com/classes/glp-1-agonists/who-should-not-take-glp-1?srsltid=AfmBOooZlNlGslp7JFOLOR1cbD-CF-smBkdKlfywkAWpTT8nTYYlBkNK)
• WHO Endorses GLP‑1 Therapy Obesity Care: Implications for Diabetes Providers – Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. (https://diabetesincontrol.com/glp-1-therapy-obesity-who-guidance-diabetes-care)
• Products – Data Briefs – Number 537 – July 2025 (https://cdc.gov/nchs/products/databriefs/db537.htm)
• WHO Issues First Guidance on Using GLP-1 Drugs to Treat Obesity (https://usnews.com/news/health-news/articles/2025-12-02/who-issues-first-guidance-on-using-glp-1-drugs-to-treat-obesity)
• WHO releases new guidance for GLP-1 weight loss drugs: What to know (https://thehill.com/homenews/nexstar_media_wire/5632067-who-releases-new-guidance-for-glp-1-weight-loss-drugs-what-to-know)